Evicenter
P&T meetings

Molgramostim Inhalation Solution

Autoimmune pulmonary alveolar proteinosis

Manufacturer
Savara
Regulatory submission
BLA resubmitted December 2025
Launch
Not announced
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

2 evidence topics · 2 sources

Healthy volunteers: systemic exposure and elimination

“In healthy people, inhaled molgramostim was well-tolerated and resulted in systemic exposure at picogram levels, which had the expected PD effects on blood leucocyte levels that mostly remained within normal ranges.” (opens the source at this quote in a new tab)

“42 subjects were enrolled” (opens the source at this quote in a new tab)

“peaked at 2 hours for all three doses and had an elimination half-life of 1.7±0.0 to 5.9±0.9 hours” (opens the source at this quote in a new tab)

Healthy volunteers: exposure proportionality

“Systemic GM-CSF exposure was non-linear” (opens the source at this quote in a new tab)